VYNE Stock Analysis: Buy, Sell, or Hold?
VYNE - VYNE Therapeutics Inc. Common Stock
$0.72
0.06 (8.98%)
▲
5d:
+7.05%
30d:
+7.84%
90d:
+14.76%
HOLD
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When VYNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: VYNE is 7.0% above its trading range ($0.67). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: VYNE is 7.0% above its trading range ($0.67). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: VYNE is currently trading at $0.72, which is considered extended relative to its 30-day fair value range of $0.64 to $0.67.
Technical Outlook: Technically, VYNE is in a strong uptrend. The price is approaching resistance at $0.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: VYNE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.00 (+204.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VYNE is in a strong uptrend. The price is approaching resistance at $0.69. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: VYNE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $2.00 (+204.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.64 -
$0.67
Company Quality Score
60/100
(BUY)
Volume Confirmation
MODERATE
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+7.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+9.0%)
- BULLISH: Trading 204.0% below Wall St target ($2.00)
Trading Range Analysis
30-Day Trading Range
$0.64 -
$0.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.62
Resistance Level
$0.69
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.40
Wall Street Target
$2.00
(+204.0%)
Revenue Growth (YoY)
-57.4%
Share & Embed Analysis
Last updated: July 14, 2026 3:00 PM ET
Data refreshes hourly during market hours. Next update: 3:59 PM
Data refreshes hourly during market hours. Next update: 3:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
